VIDEO: ‘Important’ IMpower010 trial uses immune checkpoint inhibition as an adjuvant therapy

ByPasi A. Jänne, MD, PhD

ByMarley V. Ghizzone

In this video, Pasi A. Jänne, MD, PhD, spoke with Healio about data from the IMpower010 trial presented at the virtual ASCO Annual Meeting.

“It’s an important trial because it highlights the use of immune checkpoint inhibition as an adjuvant therapy,” Jänne, director of the Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science and Chen-Huang Center for EGFR Mutant Lung Cancers, and senior physician and professor of medicine at Harvard Medical School, said.

Published by:

Sources/Disclosures

Collapse

Source: Healio Interview; Wakelee HA, et al. Abstract 8500. Scheduled for presentation at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.

Disclosures: Janne reports receiving stock and other ownership interests from Gatekeeper Pharmaceuticals and Loxo Oncology; serving in a consulting or advisory role for Araxes Pharma, AstraZeneca, Bayer, Biocartis, Biocartis, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, Eisai, Ignyta, Lilly, LOXO, Merrimack, Mirati Therapeutics, Novartis, Nuvalent Inc., Pfizer, Roche/Genentech, Sanofi, SFJ Pharmaceuticals Group, Silicon Therapeutics, Takeda and Voronoi; and receiving research funding from Astellas Pharma, AstraZeneca, Boehringer Ingelhei, Daiichi Sankyo, Lilly, Puma Biotechnology, Revolution Medicines and Takeda.

Take Homes in Lung Cancer

Read more

VIDEO: ‘Important’ IMpower010 trial uses immune checkpoint inhibition as an adjuvant therapy

Related Content